Stallergenes Greer PLC: Tibor Nemes Appointed Global Head of Technical Operations

LONDON--()--Regulatory News:

Stallergenes Greer plc (the "Company")(Euronext Paris:STAGR)(Paris:STAGR), a biopharmaceutical company specializing in treatments for respiratory allergies, today announced the appointment of Tibor Nemes as Global Head of Technical Operations.

Tibor has 20 years of Operations experience in the biotech and pharmaceutical industry in both Europe and in the United States with a proven track record of leadership in engineering, process development and the manufacturing of biologics, solids, and sterile dosage forms. Since 2008, he held roles of increasing responsibility at Novartis most recently heading Operations for Manufacturing Strategy and Business Development & Licensing within Global Technical Operations.

Fereydoun Firouz, Chairman and Chief Executive Officer of Stallergenes Greer, said:

"I am delighted to welcome Tibor as our Global Head of Technical Operations. Given his background and the recent challenges at our Antony site, the timing of his arrival at Stallergenes Greer is ideal. In this new role, Tibor will lead our Technical Operations organization, craft our global manufacturing strategy, and ensure our teams execute to the highest standards of operational excellence. He will play a vital role in helping our Company become the leading biopharmaceutical company focused on enabling people with allergies to live normal lives."

ABOUT STALLERGENES GREER PLC

Headquartered in London (UK), Stallergenes Greer plc is a global healthcare company specializing in the diagnosis and treatment of allergies through the development and commercialization of allergy immunotherapy products and services. Stallergenes Greer plc is the parent company of GREER Laboratories, Inc. (whose registered office is in the U.S.) and Stallergenes S.A.S. (whose registered office is in France).

Trading information:
Name: Stallergenes Greer
ISIN: GB00BZ21RF93 1 - Ticker: STAGR
ICB classification: 4577
Market: Euronext Paris regulated market

Additional information is available at http://www.stallergenesgreer.com

Suggested Articles

There's no evidence personal patient information leaked during the 11-week breach, but the same can't be said about Sangamo's own secrets.

Through a new online tracker, AllTrials names sponsors who fail to report clinical trial results on time per the FDAAA Final Rule.

The new solution aims to streamline the incorporation of human genomic data into clinical trial designs.